Royalty Pharma director granted 4,545 RSUs

Engelbert Catherine M. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Engelbert Catherine M. reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Catherine M. Engelbert received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. The award was granted at no cash cost to her and was made under the company’s 2020 Independent Director Equity Incentive Plan.

The restricted stock units are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of shareholders, subject to plan and award terms. Following this grant, Engelbert directly holds 55,673 Class A Ordinary Shares.

Insider Trade Summary

Grant/Award: 4,545 shares

Grant/Award 1 txn

Insider Engelbert Catherine M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	4,545	$0.00	$0.00

Holdings After Transaction: Class A Ordinary Shares — 55,673 shares (Direct)

Footnotes (1)

1. F1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Key Figures

RSUs granted: 4,545 shares Grant price: $0.0000 per share Shares owned after grant: 55,673 shares +1 more

4 metrics

RSUs granted 4,545 shares Restricted stock units of Class A Ordinary Shares granted to director

Grant price $0.0000 per share Reported transaction price per share for the RSU award

Shares owned after grant 55,673 shares Total Class A Ordinary Shares directly held by Engelbert after transaction

Vesting trigger Earlier of one year or next annual meeting Schedule for 100% vesting of the restricted stock units

Key Terms

restricted stock units, Equity Incentive Plan, vest

3 terms

restricted stock units financial

"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Equity Incentive Plan financial

"under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vest financial

"generally scheduled to vest 100% on the earlier of (i) the one-year anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Royalty Pharma (RPRX) disclose about Catherine M. Engelbert’s latest equity award?

Royalty Pharma reported that director Catherine M. Engelbert received 4,545 restricted stock units of Class A Ordinary Shares. The grant was made under the 2020 Independent Director Equity Incentive Plan at no cash cost to her.

How many Royalty Pharma shares does Catherine M. Engelbert hold after this Form 4 transaction?

After the reported award, Catherine M. Engelbert directly holds 55,673 Class A Ordinary Shares of Royalty Pharma. This total reflects her updated ownership position following the grant of 4,545 restricted stock units disclosed in the filing.

What type of security was granted to Catherine M. Engelbert by Royalty Pharma (RPRX)?

She was granted restricted stock units representing 4,545 Class A Ordinary Shares of Royalty Pharma. These units are an equity-based award under the 2020 Independent Director Equity Incentive Plan, rather than a cash payment.

When do Catherine M. Engelbert’s new Royalty Pharma restricted stock units vest?

The restricted stock units generally vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of shareholders. Vesting remains subject to the terms of the plan and the applicable award agreement.

Was there a purchase price for Catherine M. Engelbert’s new Royalty Pharma shares?

The filing shows a transaction price per share of $0.0000 for the 4,545 restricted stock units granted. This indicates the award was provided as compensation, not acquired through an open-market purchase by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Engelbert Catherine M.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/05/2026		A		4,545(1)	A	$0	55,673	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Catherine M. Engelbert	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)